<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00441740</url>
  </required_header>
  <id_info>
    <org_study_id>CT/04.04</org_study_id>
    <nct_id>NCT00441740</nct_id>
  </id_info>
  <brief_title>Randomized Trial With Vinorelbine and Gemcitabine Versus Docetaxel and Gemcitabine in Patients With Non-Small Cell Lung Cancer</brief_title>
  <official_title>Vinorelbine and Gemcitabine Versus Docetaxel and Gemcitabine as First Line Treatment in Patients With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC). A Prospective , Multicenter, Randomized, Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Oncology Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital of Crete</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hellenic Oncology Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether the gemcitabine/vinorelbine combination
      versus the gemcitabine/docetaxel combination as first line treatment, offers a survival
      advantage in patients with locally advanced/metastatic NSCLC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cisplatin-based chemotherapy represented the backbone of treatment of advanced NSCLC.
      However, several trials comparing platinum versus non-platinum based chemotherapy regimens
      failed to demonstrate a statistically significant difference in terms of time to tumor
      progression or survival. Newer agents such as gemcitabine, docetaxel and vinorelbine have
      shown significant activity in the treatment of NSCLC. Gemcitabine/vinorelbine combination as
      first line treatment has demonstrated a response rate (RR) of 18-43% and a median overall
      survival (OS) of 9.8-13 months. Similarly, the gemcitabine/docetaxel combination has shown a
      RR 32-35% and a median OS of 9-12 months. Given their proven efficacy, the combination of
      these two doublets, would be interesting.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Objective responses confirmed by CT or MRI (on 3rd and 6th cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to tumor progression</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Toxicity assessment on each chemotherapy cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Assessment every two cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">419</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DG</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>Vinorelbine (oral) 70 mg/m2, on days 1 and 15 every 4 weeks for 6 cycles</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Navelbine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine 900 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 75 mg/m2 intravenous on day 8 every 3 weeks for 6 cycles</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine 1000 mg/m2 intravenous, on days 1 and 8 every 3 weeks for 6 cycles</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed, unresectable locally advanced (stage IIIB
             with pleural effusion) and/or metastatic (stage IV) NSCLC

          -  No previous therapy for advanced/metastatic NSCLC is allowed

          -  Age &gt; 18 years

          -  Bidimensionally measurable disease

          -  Performance status (WHO) 0-2

          -  Adequate liver (serum bilirubin &lt; 1.5 times the upper normal limit (UNL); AST and ALT
             &lt; 2.5 times the UNL in the absence of demonstrable liver metastases, or &lt; 5 times the
             UNL in the presence of liver metastases); adequate renal function (serum creatinine &lt;
             1.5 times the UNL); and bone marrow (neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x
             109 /L) function

          -  Previous radiotherapy, either in the adjuvant setting or for the treatment of
             metastatic disease is allowed provided that the measurable lesions are outside the
             radiation fields

          -  Life expectancy of more than 3 months

          -  Patient able to take oral medication

          -  At least 4 weeks since prior radiotherapy

          -  Written informed consent

        Exclusion Criteria:

          -  Active infection

          -  History of significant cardiac disease (unstable angina, congestive heart failure,
             myocardial infarction within the previous 6 months, ventricular arrhythmias)

          -  Malnutrition (loss of ≥ 20% of the original body weight)

          -  Performance status: 3-4

          -  Sensor or motor neuropathy &gt; grade I

          -  Second primary malignancy, except for non-melanoma skin cancer

          -  Psychiatric illness or social situation that would preclude study compliance

          -  Pregnant or lactating women

          -  Known, symptomatic central nervous system metastases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vassilis Georgoulias, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Crete, Dep of Medical Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University General Hospital of Alexandroupolis, Dep of Medical Oncology</name>
      <address>
        <city>Alexandroupolis</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot; General Hospital, 1st, 3rd, 8th Dep of Pulmonary Diseases</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Laikon&quot; General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Metaxa's&quot; Anticancer Hospital of Piraeus,1st Dep of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>401 Military Hospital, Medical Oncology Unit</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Air Forces Military Hospital, Dep of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IASO&quot; General Hospital of Athens, 1st Dep of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sismanogleio General Hospital, 1st, 2nd Dep of Pulmonary Diseases</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Theagenion&quot; Anticancer Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2007</study_first_submitted>
  <study_first_submitted_qc>February 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2007</study_first_posted>
  <last_update_submitted>October 29, 2008</last_update_submitted>
  <last_update_submitted_qc>October 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2008</last_update_posted>
  <responsible_party>
    <name_title>V.Georgoulias</name_title>
    <organization>Hellenic Oncology Research Group</organization>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>1st line treatment</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Vinorelbine</keyword>
  <keyword>Docetaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

